GlaxoSmithKline taps UC’s CRISPR expertise to speed drug discovery

By Public Affairs, UC Berkeley on June 13, 2019
Jennifer Doudna and Jonathan Weissman are the key players in a new collaboration with GlaxoSmithKline to apply CRISPR techniques to the discovery of new drug targets, potentially leading to new therapies for genetic diseases.

UNITY Biotechnology, Inc. and UCSF Enter Exclusive License Agreement on alpha-Klotho Protein for the Treatment of Age-Related Cognitive Decline

By Laura Kurtzman on June 05, 2019
SAN FRANCISCO, May 29, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc.

Exploring a Patient-First Partnership

By Adelle Infante on May 23, 2019
Published on on May 23, 2019 - Link Making a Match Do your passions overlap? Do you have the same long-term goals? Are you willing to do long-distance from the Chicago area to San Francisco? Answering these questions may be reminiscent of online dating, but they have an important...

Tumor Regression Discovery Gets FDA Green Light

May 16, 2019
Once considered an undruggable target, the Shokat group discovered a novel, small molecule approach to induce tumor regression. The US FDA has cleared the IND application for clinical development.

Tmunity and UCSF Announce Collaboration

By Laura Kurtzman & Mike Beyer on May 02, 2019
Tmunity and UC San Francisco Announce Exclusive License and Research Collaboration to Advance TCR T Cell Therapies for Pediatric Cancers   – Collaboration will broaden Tmunity’s pipeline to include a glioma T cell therapy engineered to express a newly discovered T cell receptor – – Initial...

Scientists Create Speech From Brain Signals

By Benedict Carey on April 24, 2019
A prosthetic voice decodes what the brain intends to say and generates (mostly) understandable speech, no muscle movement needed.

One Day There May Be a Drug to Turbocharge the Brain. Who Should Get It?

By Carl Zimmer on April 03, 2019
The Mysterious Hormone Called Klotho.

CRISPR-mediated Activation to Reduce Obesity

By UCSF on January 19, 2019
Catalyst awardees, Nadav Ahituv, PhD and Navneet Matharu, PhD, apply CRISPR-mediated activation to obesity. Here are the results:

Sana Biotechnology Launches Focusing on Engineering Cells to Create a New Class of Medicines

January 04, 2019
- Comprised of an experienced leadership team, visionary investors, and renowned scientists in cell therapy, gene therapy, and gene editing - Brings together a portfolio of potential medicines and technologies - Led by Steve Harr, M.D. as CEO and Hans Bishop as Executive Chairman

Sana Biotechnology Launches

By UCSF on January 04, 2019
UCSF's Sonja Schrepfer helps found startup Sana Biotechnology, as they launch with a focus on engineering cells to create a new class of medicines.